Clinical Medicine - Posters J
Dr. Polivka, Lörinc
Y5BXMU
SE Pulmonológia Klinika
+36306585547
polivka.lorinc@outlook.com
Waning of SARS-Cov-2 vaccine effectiveness against delta variant in COPD patients
Lorinc Polivka1, Istvan Valyi-Nagy2, Zoltan Szekanecz3, Krisztina Bogos4, Hajnalka Vago5, Anita Kamondi6, Ferenc Fekete7, Janos Szlavik2, György Surjan8,9, Orsolya Surjan8, Peter Nagy10,11,12, Zsuzsa Schaff13, Zoltan Kiss14, Cecilia Müller8, Miklos Kasler15, Veronika Müller1
1 Department of Pulmonology, Semmelweis University, 1085 Budapest, Hungary
2 Central Hospital of Southern Pest - National Institute of Hematology and Infectious Diseases, 1097 Budapest, Hungary
3 Department of Rheumatology, Faculty of Medicine, University of Debrecen, 4012 Debrecen, Hungary
4 National Korányi Institute of Pulmonology, 1122 Budapest, Hungary
5 Heart and Vascular Centre, Dept. of Sports Medicine, Semmelweis University, 1122 Budapest, Hungary
6 National Institute of Mental Health, Neurology and Neurosurgery, 1145 Budapest, Hungary
7 Heim Pál National Pediatric Institute, 1089 Budapest, Hungary
8 National Public Health Center, 1097 Budapest, Hungary
9 Department of Digital Health Sciences, Semmelweis University, 1085 Budapest, Hungary
10 Department of Molecular Immunology and Toxicology and the National Tumor Biology Laboratory, National Institute of Oncology, 1122 Budapest, Hungary
11 Department of Anatomy and Histology, Laboratory of Redox Biology, University of Veterinary Medicine, 1078 Budapest, Hungary
12 Chemistry Institute, University of Debrecen, 4012 Debrecen, Hungary
13 Department of Pathology and Forensic Medicine, Semmelweis University, 1091 Budapest, Hungary
14 2nd Department of Internal Medicine and Nephrological Center, University of Pécs, 7624 Pécs, Hungary
15 Ministry of Interior, 1051 Budapest, Hungary
Poszter
Clinical Medicine - Posters J
English
Clinical Medicine
Although the COVID-19 pandemic is profoundly changing, data on the effect of vaccination and duration of protection can still be advantageous, especially for patients with COPD, who are more vulnerable to respiratory infections.
The Hungarian-COVID-19 registry was retrospectively investigated for vaccine effectiveness (VE) and daily risk for infection and hospitalization by time since the last vaccination and vaccine type in adults with COPD diagnosis and an exact-matched control group during the Delta VOC wave in Hungary. For the matching sex, age, major comorbidities, vaccination status, and prior infection was used on August 23, 2021.
The study population included 373 962 cases divided into COPD patients (age: 66.67±12.66) and a 1:1 matched group (age: 66.73±12.67). In both groups, the female/male ratio was 52.2:47.7.
There was no significant difference between the groups in daily risks for infection or hospitalization among the unvaccinated. Regarding vaccinated cases, a faster decline of effectiveness was noted for hospitalization prevention in the COPD group regardless of vaccine type. The VE reduction in this group was from 90.1% (mRNA) and 87.8% (other) to 48.8% and 34.1% respectively in 180 days. Based on the time-stratified multivariate Cox analysis of the vaccinated cases, the hazard ratio was 1.09 (95% CI: 1.05-1.14) for infection and 1.87 (95% CI: 1.59-2.19) for hospitalization in the COPD group.
Based on our study COPD patients are at higher risk for SARS-Cov2 VE waning and have altogether a higher risk for infection and need for hospitalization emphasizing suggestion for revaccination measures in this patient population.
The Center for Health Technology Assessment of Semmelweis University participated in the project on a contractual basis made with the Ministry of Human Resources of Hungary and received funding.
Semmelweis University, Károly Rácz Doctoral School of Clinical Medicine
Prof. Dr. Müller Veronika
I do not give consent to the publication of my abstract on the website of the congress.
Szabad
elfogadva
poszter
nem rendelkezett róla
7508
11:12
11:17
Lorinc Polivka1, Istvan Valyi-Nagy2, Zoltan Szekanecz3, Krisztina Bogos4, Hajnalka Vago5, Anita Kamondi6, Ferenc Fekete7, Janos Szlavik2, György Surjan8,9, Orsolya Surjan8, Peter Nagy10,11,12, Zsuzsa Schaff13, Zoltan Kiss14, Cecilia Müller8, Miklos Kasler15, Veronika Müller1
1 Department of Pulmonology, Semmelweis University, 1085 Budapest, Hungary
2 Central Hospital of Southern Pest - National Institute of Hematology and Infectious Diseases, 1097 Budapest, Hungary
3 Department of Rheumatology, Faculty of Medicine, University of Debrecen, 4012 Debrecen, Hungary
4 National Korányi Institute of Pulmonology, 1122 Budapest, Hungary
5 Heart and Vascular Centre, Dept. of Sports Medicine, Semmelweis University, 1122 Budapest, Hungary
6 National Institute of Mental Health, Neurology and Neurosurgery, 1145 Budapest, Hungary
7 Heim Pál National Pediatric Institute, 1089 Budapest, Hungary
8 National Public Health Center, 1097 Budapest, Hungary
9 Department of Digital Health Sciences, Semmelweis University, 1085 Budapest, Hungary
10 Department of Molecular Immunology and Toxicology and the National Tumor Biology Laboratory, National Institute of Oncology, 1122 Budapest, Hungary
11 Department of Anatomy and Histology, Laboratory of Redox Biology, University of Veterinary Medicine, 1078 Budapest, Hungary
12 Chemistry Institute, University of Debrecen, 4012 Debrecen, Hungary
13 Department of Pathology and Forensic Medicine, Semmelweis University, 1091 Budapest, Hungary
14 2nd Department of Internal Medicine and Nephrological Center, University of Pécs, 7624 Pécs, Hungary
15 Ministry of Interior, 1051 Budapest, Hungary